La vendita allo scoperto per Ligand Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Ligand Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Ligand Pharmaceuticals (NASDAQ:LGND) Azioni, Report sulle vendite allo scoperto

Ligand Pharmaceuticals

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals Inc

RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Outperform and raises the price target from $130 to $140.

News

Price Target

Analyst Ratings

LGND

RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $140

Benchmark analyst Robert Wasserman maintains Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Buy and raises the price target from $110 to $135.

Benchmark Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $135

Barclays analyst Balaji Prasad maintains Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Overweight and raises the price target from $125 to $150.

Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $150

Oppenheimer analyst Leland Gershell maintains Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Outperform and raises the price target from $135 to $147.

Oppenheimer Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $147

In the preceding three months, 7 analysts have released ratings for Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Ligand Pharmaceuticals, presenting an average target of $138.71, a high estimate of $157.00, and a low estimate of $110.00. Witnessing a positive shift, the current average has risen by 4.95% from the previous average price target of $132.17.
<img src="https://www.benzinga.com/files/images/story/2024/1731078017_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Ligand Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$157.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$157.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$157.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ligand Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ligand Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Ligand Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Ligand Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LGND/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ligand Pharmaceuticals analyst ratings.</a>
<h2>About Ligand Pharmaceuticals</h2>
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
<h3>A Deep Dive into Ligand Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Ligand Pharmaceuticals displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 57.52%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Ligand Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -124.99%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -6.56%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Ligand Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.83%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Buy and maintains $157 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $157 Price Target

WIIM

Ligand Pharmaceuticals shares are trading higher after the company reported worse-than-expected Q3 financial results and raised its FY24 guidance.

2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50)

Guidance

Ligand Pharmaceuticals Raises FY24 Adj EPS Guidance from $5.00-$5.50 to $5.50-$5.70 vs $5.39 Est; Sales from $140.00M-$157.00M to $160.00M-$165.00M vs $156.38M Est

Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) reported quarterly earnings of $1.84 per share which beat the analyst consensus estimate of $1.35 by 36.3 percent. This is a 80.39 percent increase over earnings of $1.02 per share from the same period last year. The company reported quarterly sales of $51.812 million which beat the analyst consensus estimate of $40.650 million by 27.46 percent. This is a 57.64 percent increase over sales of $32.868 million the same period last year.

Earnings

Earnings Beats

Ligand Pharmaceuticals Q3 2024 Adj. EPS $1.84 Beats $1.35 Estimate, Sales $51.812M Beat $40.650M Estimate

Barclays analyst Balaji Prasad maintains Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Overweight and raises the price target from $110 to $125.

Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $125

During the last three months, 7 analysts shared their evaluations of Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Ligand Pharmaceuticals and provided 12-month price targets. The average target is $133.71, accompanied by a high estimate of $157.00 and a low estimate of $110.00. Surpassing the previous average price target of $128.60, the current average has increased by 3.97%.
<img src="https://www.benzinga.com/files/images/story/2024/1729515654_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Ligand Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$157.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$144.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$130.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ligand Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ligand Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Ligand Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Ligand Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LGND/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ligand Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Ligand Pharmaceuticals</h2>
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
<h3>Financial Milestones: Ligand Pharmaceuticals's Journey</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Ligand Pharmaceuticals displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 57.52%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -124.99%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Ligand Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -6.56%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ligand Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.83%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Ligand Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know

7 analysts have expressed a variety of opinions on Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Ligand Pharmaceuticals and provided 12-month price targets. The average target is $133.71, accompanied by a high estimate of $157.00 and a low estimate of $110.00. Marking an increase of 3.97%, the current average surpasses the previous average price target of $128.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1729512020_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Ligand Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$157.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$144.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$130.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ligand Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ligand Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Ligand Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LGND/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ligand Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Ligand Pharmaceuticals</h2>
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
<h3>Key Indicators: Ligand Pharmaceuticals's Financial Health</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Ligand Pharmaceuticals displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 57.52%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ligand Pharmaceuticals's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -124.99%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -6.56%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Ligand Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.83%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Ligand Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Buy and raises the price target from $144 to $157.

HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $157

8 analysts have expressed a variety of opinions on Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $132.88, with a high estimate of $144.00 and a low estimate of $110.00. Witnessing a positive shift, the current average has risen by 2.48% from the previous average price target of $129.67.
<img src="https://www.benzinga.com/files/images/story/2024/1727974857_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Ligand Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$144.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Hewitt</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$144.00</td>
<td>$144.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ligand Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ligand Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Ligand Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ligand Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LGND/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ligand Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Ligand Pharmaceuticals</h2>
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
<h3>Financial Milestones: Ligand Pharmaceuticals's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Ligand Pharmaceuticals displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 57.52%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ligand Pharmaceuticals's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -124.99%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Ligand Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -6.56%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Ligand Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -5.83%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Ligand Pharmaceuticals

Oppenheimer analyst Leland Gershell initiates coverage on Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Outperform rating and announces Price Target of $135.

Initiation

Oppenheimer Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $135

A large exercise of company stock options by Matthew E Korenberg, President &amp; COO at Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) was disclosed in a new SEC filing on September 24, as part of an insider exercise.
What Happened: Korenberg, President &amp; COO at Ligand Pharmaceuticals, exercised stock options for 14,754 shares of LGND stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000886163/000200101124000087//Archives/edgar/data/886163/000200101124000087/0002001011-24-000087-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The exercise price of the options was $51.8 per share.
Ligand Pharmaceuticals shares are trading down 0.73% at $98.81 at the time of this writing on Wednesday morning. Since the current price is $98.81, this makes Korenberg's 14,754 shares worth $704,336.
<h3>Get to Know Ligand Pharmaceuticals Better</h3>
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
<h3>Financial Insights: Ligand Pharmaceuticals</h3>
Revenue Growth: Ligand Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 57.52%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 93.0%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Ligand Pharmaceuticals's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of -2.88.
</li>
</ul>
Debt Management: Ligand Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 42.68, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 13.39 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 17.99, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000886163">Check Out The Full List Of Ligand Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Insider Move: Matthew E Korenberg Exercises Options, Realizing $704K At Ligand Pharmaceuticals

Octavio Espinoza, Chief Financial Officer at Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>), reported a large exercise of company stock options on September 19, according to a new SEC filing.
What Happened: Espinoza, Chief Financial Officer at Ligand Pharmaceuticals, made a strategic move by exercising stock options for 1,486 shares of LGND as detailed in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000886163/000200101124000084//Archives/edgar/data/886163/000200101124000084/0002001011-24-000084-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $36,527.
Currently, Ligand Pharmaceuticals shares are trading down 0.76%, priced at $104.21 during Friday's morning. This values Espinoza's 1,486 shares at $36,527.
<h3>Unveiling the Story Behind Ligand Pharmaceuticals</h3>
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
<h3>Ligand Pharmaceuticals's Financial Performance</h3>
Revenue Growth: Ligand Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 57.52%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 93.0%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Ligand Pharmaceuticals's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of -2.88.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 45.07 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 14.14 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Ligand Pharmaceuticals's EV/EBITDA ratio stands at 19.13, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Cracking Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000886163">Check Out The Full List Of Ligand Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Update: Octavio Espinoza Engages In Options Exercise At Ligand Pharmaceuticals

On September 18, it was revealed in an SEC filing that Matthew E Korenberg, President &amp; COO at Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) executed a significant exercise of company stock options.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000886163/000200101124000082//Archives/edgar/data/886163/000200101124000082/0002001011-24-000082-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Korenberg, President &amp; COO at Ligand Pharmaceuticals, a company in the Health Care sector, just exercised stock options worth 5,774 shares of LGND stock with an exercise price of $58.49.
Ligand Pharmaceuticals shares are currently trading down by 0.0%, with a current price of $103.68 as of Thursday morning. This brings the total value of Korenberg's 5,774 shares to $260,951.
<h3>Discovering Ligand Pharmaceuticals: A Closer Look</h3>
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
<h3>Breaking Down Ligand Pharmaceuticals's Financial Performance</h3>
Positive Revenue Trend: Examining Ligand Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 57.52% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 93.0%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Ligand Pharmaceuticals's EPS reflects a decline, falling below the industry average with a current EPS of -2.88.
</li>
</ul>
Debt Management: Ligand Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 44.5 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 13.96 is above industry norms, reflecting an elevated valuation for Ligand Pharmaceuticals's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Ligand Pharmaceuticals's EV/EBITDA ratio, surpassing industry averages at 18.86, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000886163">Check Out The Full List Of Ligand Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Matthew E Korenberg At Ligand Pharmaceuticals Executes Options Exercise, Realizing $260K

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function preservation that accrued over two years
Conversion to full approval based on results from the PROTECT Study, where FILSPARI delivered superior long-term kidney function preservation compared to the active comparator irbesartan in the only Phase 3 head-to-head trial conducted in IgAN
As an oral, non-immunosuppressive and dual acting, once-daily medicine with superior long-term results vs. irbesartan, FILSPARI has the potential to become foundational care in IgAN
Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI

Legal

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI

Ligand Pharmaceuticals Q3 2024 Earnings Preview

Ligand Pharmaceuticals beats Q3 top and bottom line estimates

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Ligand Pharma (LGND – Research Report). The associated price target...

Ligand Pharma's Strong Financial Performance and Strategic Growth Justifies Buy Rating

Ligand Pharmaceuticals Inc ( ($LGND) ) has released its Q3 earnings. Here is a breakdown of the information Ligand Pharmaceuticals Inc presented to...

Ligand Pharmaceuticals Reports Strong Q3 2024 Growth

Barclays raised the firm's price target on Ligand (LGND) to $150 from $125 and keeps an Overweight rating on the shares following the "beat and rai...

Ligand price target raised to $150 from $125 at Barclays

Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PepGen Inc. (PEPG – Research Report), Ligand Pharma ...

Analysts Are Bullish on Top Healthcare Stocks: PepGen Inc. (PEPG), Ligand Pharma (LGND)

In a report released yesterday, Douglas Miehm from RBC Capital maintained a Buy rating on Ligand Pharma (LGND – Research Report), with a price targ...

RBC Capital Keeps Their Buy Rating on Ligand Pharma (LGND)

In a report released today, Balaji Prasad from Barclays assigned a Buy rating to Ligand Pharma (LGND – Research Report), with a price target of $15...

Ligand Pharma (LGND) Gets a Buy from Barclays

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

LGNDZ

LGNXZ

LGNYZ

LGNZZ

PEPG

VCYT

Press Releases

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

Biotech

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

Ligand Reports Second Quarter 2024 Financial Results

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Comments

Ligand Pharmaceuticals

Vendite allo scoperto

Ligand Pharmaceuticals (NASDAQ:LGND) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO